https://www.snbl-nds.com/ https://www.snbl-nds.com/business/ https://www.snbl-nds.com/technology/ https://www.snbl-nds.com/application/ https://www.snbl-nds.com/partnering/ https://www.snbl-nds.com/partnering/feasibility/ https://www.snbl-nds.com/news/ https://www.snbl-nds.com/news/2025/ https://www.snbl-nds.com/news/2024-1/ https://www.snbl-nds.com/news/2023-1/ https://www.snbl-nds.com/news/2022-1/ https://www.snbl-nds.com/news/2021-1/ https://www.snbl-nds.com/news/2012/ https://www.snbl-nds.com/contact/ https://www.snbl-nds.com/privacy-policy/ https://www.snbl-nds.com/privacy-policy/blog/ https://www.snbl-nds.com/2025/10/06/snbl-s-subsidiary-snld-announces-posters-to-be-presented-at-the-upcoming-international-congress-of-parkinson-s-disease-and-movement-disorders/ https://www.snbl-nds.com/2025/05/01/satsuma-pharmaceuticals-announces-u-s-fda-approval-for-atzumi-dihydroergotamine-nasal-powder-for-the-acute-treatment-of-migraine/ https://www.snbl-nds.com/2025/03/24/snbl-s-subsidiary-snld-announces-its-abstract-accepted-at-the-upcoming-77th-american-academy-of-neurology-aan-2025-annual-meeting/ https://www.snbl-nds.com/2024/11/26/snbl-s-subsidiary-satsuma-pharmaceuticals-receives-fda-acceptance-of-nda-resubmission-of-sts101-for-the-acute-treatment-of-migraine-with-or-without-aura/ https://www.snbl-nds.com/2024/10/31/snbl-s-subsidiary-satsuma-pharmaceuticals-resubmits-new-drug-application-for-sts101-for-acute-treatment-of-migraine-with-or-without-aura/ https://www.snbl-nds.com/2024/01/18/fda-issues-complete-response-letter-for-satsuma-s-sts101/ https://www.snbl-nds.com/2023/06/26/snbl-announces-results-of-collaboration-research-with-hamamatsu-university-school-of-medicine-using-snbl-s-nose-to-brain-delivery-technology/ https://www.snbl-nds.com/2023/05/19/satsuma-pharmaceuticals-announces-fda-acceptance-of-nda-for-sts101-a-novel-and-investigational-dhe-nasal-powder-product-for-the-acute-treatment-of-migraine/ https://www.snbl-nds.com/2023/04/17/snbl-enters-into-definitive-agreement-to-acquire-satsuma-pharmaceuticals-inc/ https://www.snbl-nds.com/2022/11/24/snbl-s-comments-on-results-from-clinical-phase-3-studies-of-sts101-an-investigational-migraine-drug-candidate-announced-by-satsuma-pharmaceuticals-inc/ https://www.snbl-nds.com/2022/11/14/satsuma-pharmaceuticals-announces-topline-results-from-the-sts101-summit-phase-3-efficacy-trial-for-the-acute-treatment-of-migraine/ https://www.snbl-nds.com/2022/09/21/satsuma-pharmaceuticals-announces-positive-results-from-the-ongoing-sts101-ascend-phase-3-open-label-long-term-safety-trial/ https://www.snbl-nds.com/2021/08/02/satsuma-pharmaceuticals-announces-first-subject-randomized-in-the-phase-3-summit-efficacy-trial-of-sts101-for-acute-treatment-of-migraine/ https://www.snbl-nds.com/2021/06/17/satsuma-pharmaceuticals-inc-announces-positive-pk-tolerability-and-safety-results-from-phase-1-trial-of-sts101-at-multiple-dose-strengths/ https://www.snbl-nds.com/2021/03/02/satsuma-pharmaceuticals-inc-announces-updated-sts101-development-plan/ https://www.snbl-nds.com/2020/09/11/satsuma-pharmaceuticals-inc-announces-topline-results-from-emergetm-phase-3-trial-of-sts101-for-the-acute-treatment-of-migraine/ https://www.snbl-nds.com/2020/08/07/satsuma-pharmaceuticals-announces-enrollment-of-first-patient-in-the-ascend-phase-iii-open-label-trial-of-sts101-for-acute-treatment-of-migraine/ https://www.snbl-nds.com/2020/06/01/satsuma-pharmaceuticals-announces-completion-of-enrollment-for-phase-iii-emerge-trial-of-sts101-for-acute-treatment-of-migraine/ https://www.snbl-nds.com/2020/05/19/satsuma-pharmaceuticals-announces-poster-presentations-on-the-american-academy-of-neurology-2020-science-highlights-virtual-platform/ https://www.snbl-nds.com/2020/05/12/satsuma-pharmaceuticals-inc-reports-sts101-development-progress-in-its-first-quarter-2020-financial-results/ https://www.snbl-nds.com/2020/02/03/satsuma-pharmaceuticals-inc-announces-publication-of-sts101-phase-1-clinical-trial-results-in-headache-the-journal-of-head-and-face-pain/ https://www.snbl-nds.com/2019/09/17/satsuma-pharmaceuticals-inc-listed-on-nasdaq/ https://www.snbl-nds.com/2019/08/23/satsuma-pharmaceuticals-announces-first-patient-dosed-in-emerge-a-phase-3-efficacy-trial-of-sts101-for-the-acute-treatment-of-migraine/ https://www.snbl-nds.com/2019/04/25/satsuma-pharmaceuticals-inc-raises-62-million-in-series-b-preferred-stock-financing/ https://www.snbl-nds.com/2019/02/21/satsuma-pharmaceuticals-inc-announces-advance-of-lead-product-candidate-sts101-into-phase-3-efficacy-trial-for-acute-migraine-in-2019/ https://www.snbl-nds.com/2018/06/19/event-snbl-will-exhibit-a-booth-showcasing-our-nasal-delivery-technology-at-wcp-2018-kyoto/ https://www.snbl-nds.com/2018/05/30/event-snbl-to-present-in-vitro-in-vivo-evaluations-of-proprietary-nose-to-brain-delivery-technology-at-crs-annual-meeting-2018/ https://www.snbl-nds.com/2018/04/02/new-website/ https://www.snbl-nds.com/2016/12/19/satsuma-pharmaceuticals-inc-completes-third-party-allocation-of-new-shares-12m-financing-accelerates-development-of-migraine-therapeutic/ https://www.snbl-nds.com/2015/06/08/homepage-renewal/ https://www.snbl-nds.com/2015/06/05/snbl-s-tr-company-at-the-bio-one-on-one-partnering-at-the-bio-international-convention-2015-in-philadelphia-june-15-18th/ https://www.snbl-nds.com/2015/03/03/snbl-concludes-an-agreement-for-a-feasibility-study-to-evaluate-its-nasal-vaccine-platform-for-prophylactic-use-of-a-cervical-cancer-immunotherapeutic/ https://www.snbl-nds.com/2014/12/24/termination-of-license-agreement-with-besins-healthcare-for-nasal-progesterone/ https://www.snbl-nds.com/2014/10/16/news-release-snbl-nasal-delivery-technology-in-the-505-b-2-forum/ https://www.snbl-nds.com/2014/08/13/business-collaboration-letter-of-intent-signed-between-snbl-and-sosei-group-corporation-and-progress-on-development-of-novel-nasal-epinephrine-product/ https://www.snbl-nds.com/2013/09/26/licensing-agreement-for-nasal-drug-delivery-technology-platform-nasal-dihydroergotamine-for-treatment-of-migraine-headache/ https://www.snbl-nds.com/2013/09/19/news-release-novel-nasal-epinephrine-shows-comparable-absorption-to-epipen-r-in-a-feasibility-study/ https://www.snbl-nds.com/2013/05/15/snbl-s-nds-division-is-featured-in-the-may-2013-edition-of-drug-development-delivery-magazine/ https://www.snbl-nds.com/2018/03/27/besins-healthcare-shin-nippon-biomedical-laboratories-ltd-announce-delivery-technology-licensing-agreement-for-intranasal-progesterone/ https://www.snbl-nds.com/2012/12/26/%CE%BCco-system-is-featured-in-the-december-2012-edition-of-ondrugdelivery-magazine/ https://www.snbl-nds.com/2012/11/13/results-of-a-meeting-with-the-us-food-and-drug-administration-fda-concerning-the-development-of-intranasal-zolmitriptan-for-migraine/ https://www.snbl-nds.com/2012/10/10/%CE%BCco-system-is-featured-in-the-september-2012-edition-of-ondrugdelivery-magazine/ https://www.snbl-nds.com/2012/06/07/snbl-s-fit-lizer-device-is-featured-in-the-june-2012-edition-of-drug-development-delivery-magazine/ https://www.snbl-nds.com/2012/05/05/%CE%BCco-system-is-featured-in-the-april-2012-edition-of-ondrugdelivery-magazine/ https://www.snbl-nds.com/2012/04/04/results-of-first-phase-i-clinical-study-for-intranasal-zolmitriptan-formulation-migraine-drug/ https://www.snbl-nds.com/2011/02/10/conclusion-of-licensing-agreement-with-pastorus/ https://www.snbl-nds.com/2010/08/19/results-of-a-meeting-with-the-us-food-and-drug-administration-fda-concerning-the-development-of-intranasal-granisetron-planning-for-a-phase-3-study-to-improve-patient-quality-of-life-qol/ https://www.snbl-nds.com/2010/08/11/intranasal-zolmitriptan-clinical-study-of-rapid-acting-migraine-drug-preparations-underway-for-us-phase-1-clinical-study/ https://www.snbl-nds.com/2010/05/12/research-progress-on-tr-flu-an-intranasal-flu-vaccine-in-dry-powder-form-first-report/